{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:11:39Z","timestamp":1775193099408,"version":"3.50.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.neurol.2020.04.027","type":"journal-article","created":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T16:09:44Z","timestamp":1596384584000},"page":"788-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention"],"prefix":"10.1016","volume":"176","author":[{"given":"J.","family":"Schoenen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Manise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Nonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Timmermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neurol.2020.04.027_bib0405","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11630590-000000000-00000","article-title":"Taking the negative view of current migraine treatments","volume":"26","author":"Tfelt-Hansen","year":"2012","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.neurol.2020.04.027_bib0410","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0333102416678382","article-title":"Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis","volume":"37","author":"Hepp","year":"2017","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0415","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/0333102419877663","article-title":"Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: a mini-review","volume":"40","author":"Tfelt-Hansen","year":"2020","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.neurol.2020.04.027_bib0420","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0333102418821662","article-title":"CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/j.neurol.2020.04.027_bib0425","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies \u2013 successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0430","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0435","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/head.13432","article-title":"CGRP, amylin, immunology, and headache medicine","volume":"59","author":"Taylor","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2020.04.027_bib0440","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1468-2982.2000.00122.x","article-title":"Habituation of visual and intensity dependence of auditory evoked cortical potentials tend to normalize just before and during the migraine attack","volume":"20","author":"\u00c1fra","year":"2000","journal-title":"Cephalalgia"},{"issue":"20","key":"10.1016\/j.neurol.2020.04.027_bib0445","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1212\/WNL.0000000000003327","article-title":"Thalamo-cortical network activity during spontaneous migraine attacks","volume":"87","author":"Coppola","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurol.2020.04.027_bib0450","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.25697","article-title":"Longitudinal neuroimaging over 30 days: temporal characteristics of migraine","volume":"87","author":"Schulte","year":"2020","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2020.04.027_bib0455","first-page":"234","article-title":"The pathophysiological conundrum of migraine","volume":"44","author":"Schoenen","year":"2017","journal-title":"Jap J Head"},{"issue":"2","key":"10.1016\/j.neurol.2020.04.027_bib0460","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0465","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s10194-018-0877-8","article-title":"Evidence of an increased neuronal activation-to-resting glucose uptake ratio in the visual cortex of migraine patients: a study comparing 18FDG-PET and visual evoked potentials","volume":"19","author":"Lisicki","year":"2018","journal-title":"J Headache Pain"},{"issue":"11","key":"10.1016\/j.neurol.2020.04.027_bib0470","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41582-019-0255-4","article-title":"The metabolic face of migraine \u2013 from pathophysiology to treatment","volume":"15","author":"Gross","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2020.04.027_bib0475","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/brain\/awz405","article-title":"Mapping migraine to a common brain network","volume":"143","author":"Burke","year":"2020","journal-title":"Brain"},{"issue":"17","key":"10.1016\/j.neurol.2020.04.027_bib0480","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1523\/JNEUROSCI.0373-15.2015","article-title":"multiple processes, complex pathophysiology","volume":"35","author":"Burstein","year":"2015","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurol.2020.04.027_bib0485","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the trigeminovascular system \u2013 40 years and counting","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2020.04.027_bib0490","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cpdd.345","article-title":"Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date","volume":"6","author":"Pellesi","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"10.1016\/j.neurol.2020.04.027_bib0495","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/0333102419844711","article-title":"Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats","volume":"39","author":"Johnson","year":"2019","journal-title":"Cephalalgia"},{"issue":"10","key":"10.1016\/j.neurol.2020.04.027_bib0500","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/head.13695","article-title":"A Popperian View on Anti-CGRP Biologics in Migraine","volume":"59","author":"Chiarugi","year":"2019","journal-title":"Headache"},{"issue":"10","key":"10.1016\/j.neurol.2020.04.027_bib0505","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1177\/0333102419840780","article-title":"A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody","volume":"39","author":"Kielbasa","year":"2019","journal-title":"Cephalalgia"},{"issue":"9","key":"10.1016\/j.neurol.2020.04.027_bib0510","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/0333102419858355","article-title":"Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.neurol.2020.04.027_bib0515","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2020.04.027_bib0520","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","author":"Lipton","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0525","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12883-020-01633-3","article-title":"Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis","volume":"20","author":"Deng","year":"2020","journal-title":"BMC Neurol"},{"issue":"22","key":"10.1016\/j.neurol.2020.04.027_bib0530","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.neurol.2020.04.027_bib0535","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.neurol.2020.04.027_bib0540","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/j.neurol.2020.04.027_bib0545","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"issue":"22","key":"10.1016\/j.neurol.2020.04.027_bib0550","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.neurol.2020.04.027_bib0555","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.neurol.2020.04.027_bib0560","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/head.13652","article-title":"A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults","volume":"59","author":"Sakai","year":"2019","journal-title":"Headache"},{"issue":"9","key":"10.1016\/j.neurol.2020.04.027_bib0565","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/head.13427","article-title":"100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies","volume":"58","author":"Rosen","year":"2018","journal-title":"Headache"},{"issue":"4","key":"10.1016\/j.neurol.2020.04.027_bib0570","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/head.13515","article-title":"Misused and misleading: \u201c100% Response Rate\u201d to galcanezumab in patients with episodic migraine","volume":"59","author":"Steiner","year":"2019","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0575","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0333102419894559","article-title":"The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving \u226550%, \u226575%, and 100% response","volume":"40","author":"Brandes","year":"2020","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0580","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0333102418772585","article-title":"Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials","volume":"39","author":"Halker Singh","year":"2019","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0585","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine","volume":"19","author":"Schwedt","year":"2018","journal-title":"J Headache Pain"},{"issue":"3","key":"10.1016\/j.neurol.2020.04.027_bib0590","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/head.13446","article-title":"The effect of beginning treatment with fremanezumab on headache and associated symptoms in the randomized phase 2 study of high frequency episodic migraine: post-hoc analyses on the first 3 weeks of treatment","volume":"59","author":"Silberstein","year":"2019","journal-title":"Headache"},{"issue":"10","key":"10.1016\/j.neurol.2020.04.027_bib0595","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/head.13654","article-title":"Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine","volume":"59","author":"Winner","year":"2019","journal-title":"Headache"},{"issue":"8","key":"10.1016\/j.neurol.2020.04.027_bib0600","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jnnp-2018-320242","article-title":"Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis","volume":"90","author":"Goadsby","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.neurol.2020.04.027_bib0605","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/head.13691","article-title":"Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the evolve studies","volume":"60","author":"Detke","year":"2020","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0610","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s10194-018-0951-2","article-title":"Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies","volume":"19","author":"F\u00f6rderreuther","year":"2018","journal-title":"J Headache Pain"},{"issue":"10161","key":"10.1016\/j.neurol.2020.04.027_bib0615","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"issue":"10203","key":"10.1016\/j.neurol.2020.04.027_bib0620","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.neurol.2020.04.027_bib0625","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"38","author":"Ashina","year":"2018","journal-title":"Cephalalgia"},{"issue":"7","key":"10.1016\/j.neurol.2020.04.027_bib0630","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/0333102419835459","article-title":"Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"39","author":"Goadsby","year":"2019","journal-title":"Cephalalgia"},{"issue":"8","key":"10.1016\/j.neurol.2020.04.027_bib0635","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/0333102419847957","article-title":"Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure","volume":"39","author":"Ruff","year":"2019","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.neurol.2020.04.027_bib0640","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/ene.14102","article-title":"Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies","volume":"27","author":"Ailani","year":"2020","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0645","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s10194-019-1069-x","article-title":"Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)","volume":"20","author":"Silberstein","year":"2019","journal-title":"J Headache Pain"},{"issue":"20","key":"10.1016\/j.neurol.2020.04.027_bib0650","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2020.04.027_bib0655","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/PPA.S182563","article-title":"Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine","volume":"12","author":"Ford","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"10.1016\/j.neurol.2020.04.027_bib0660","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1177\/0333102418789072","article-title":"Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab","volume":"38","author":"Buse","year":"2018","journal-title":"Cephalalgia"},{"issue":"12","key":"10.1016\/j.neurol.2020.04.027_bib0665","doi-asserted-by":"crossref","first-page":"e1152","DOI":"10.1212\/01.wnl.0000544321.19316.40","article-title":"Fremanezumab for preventive treatment of migraine: functional status on headache-free days","volume":"91","author":"VanderPluym","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.neurol.2020.04.027_bib0670","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1177\/0333102419854082","article-title":"Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine","volume":"39","author":"Ashina","year":"2019","journal-title":"Cephalalgia"},{"issue":"14","key":"10.1016\/j.neurol.2020.04.027_bib0675","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1177\/0333102419888222","article-title":"Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions","volume":"39","author":"Ashina","year":"2019","journal-title":"Cephalalgia"},{"issue":"5","key":"10.1016\/j.neurol.2020.04.027_bib0680","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","article-title":"Vascular safety of erenumab for migraine prevention","volume":"94","author":"Kudrow","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13760-014-0313-z","article-title":"Diagnosis, pathophysiology and management of chronic migraine: a proposal of the Belgian Headache Society","volume":"115","author":"Paemeleire","year":"2015","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.neurol.2020.04.027_bib0690","first-page":"1","article-title":"Efficacy and safety of external trigeminal neurostimulation in the prevention of chronic migraine: an open-label trial","volume":"2","author":"Birlea","year":"2019","journal-title":"Cephalalgia Rep"},{"issue":"8","key":"10.1016\/j.neurol.2020.04.027_bib0695","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/head.13615","article-title":"Lamotrigine in the prevention of migraine with aura: a narrative review","volume":"59","author":"Buch","year":"2019","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0700","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s10194-018-0927-2","article-title":"Migraine induction with calcitonin gene-related peptide in patients from erenumab trials","volume":"19","author":"Christensen","year":"2018","journal-title":"J Headache Pain"},{"issue":"2","key":"10.1016\/j.neurol.2020.04.027_bib0705","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/head.13729","article-title":"Non-responders to treatment with antibodies to the CGRP-Receptor may profit from a switch of antibody class","volume":"60","author":"Ziegeler","year":"2020","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0710","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-019-1018-8","article-title":"Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination","volume":"20","author":"Raffaelli","year":"2019","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0715","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","article-title":"European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention","volume":"20","author":"Sacco","year":"2019","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0720","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","article-title":"European Headache Federation School of Advanced Studies (EHF-SAS). Blocking CGRP in migraine patients \u2013 a review of pros and cons","volume":"18","author":"Deen","year":"2017","journal-title":"J Headache Pain"},{"issue":"9","key":"10.1016\/j.neurol.2020.04.027_bib0725","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/0333102419829007","article-title":"Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials","volume":"39","author":"Xu","year":"2019","journal-title":"Cephalalgia"},{"issue":"9","key":"10.1016\/j.neurol.2020.04.027_bib0730","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.tips.2016.06.002","article-title":"Wiping Out CGRP: Potential Cardiovascular Risks","volume":"37","author":"MaassenVanDenBrink","year":"2016","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.neurol.2020.04.027_bib0735","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/head.13316","article-title":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina","volume":"58","author":"Depre","year":"2018","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.neurol.2020.04.027_bib0740","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","article-title":"European Headache Federation School of Advanced Studies (EHF-SAS). CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?","volume":"20","author":"Favoni","year":"2019","journal-title":"J Headache Pain"},{"issue":"3","key":"10.1016\/j.neurol.2020.04.027_bib0745","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/0333102419896760","article-title":"Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier","volume":"40","author":"Noseda","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2020.04.027_bib0750","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1749-6632.1992.tb22783.x","article-title":"Calcitonin gene-related peptides and neuromuscular interactions","volume":"657","author":"Changeux","year":"1992","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"10.1016\/j.neurol.2020.04.027_bib0755","doi-asserted-by":"crossref","first-page":"e113959","DOI":"10.1371\/journal.pone.0113959","article-title":"Role of calcitonin gene-related peptide in functional adaptation of the skeleton","volume":"9","author":"Sample","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.neurol.2020.04.027_bib0760","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1111\/head.13414","article-title":"Recommendations on the use of anti-CGRP monoclonal antibodies in children and adolescents","volume":"58","author":"Szperka","year":"2018","journal-title":"Headache"},{"issue":"8","key":"10.1016\/j.neurol.2020.04.027_bib0765","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1368-5031.2005.00612.x","article-title":"Topiramate 100mg\/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials","volume":"59","author":"Bussone","year":"2005","journal-title":"Int J Clin Pract"},{"issue":"5","key":"10.1016\/j.neurol.2020.04.027_bib0770","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1177\/0333102418801579","article-title":"Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed","volume":"39","author":"Vo","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neurol.2020.04.027_bib0775","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12916-015-0522-1","article-title":"New players in the preventive treatment of migraine","volume":"13","author":"Mitsikostas","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.neurol.2020.04.027_bib0780","doi-asserted-by":"crossref","DOI":"10.1111\/head.13776","article-title":"Acceptance and Commitment Therapy (ACT) vs Erenumab for High Frequency Episodic Migraine Without Aura: Time to Take the Gloves Off!","author":"Grazzi","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2020.04.027_bib0785","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1212\/WNL.0b013e3182825055","article-title":"Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial","volume":"80","author":"Schoenen","year":"2013","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurol.2020.04.027_bib0790","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/13696998.2018.1457533","article-title":"Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective","volume":"21","author":"Lipton","year":"2018","journal-title":"J Med Econ"},{"issue":"10","key":"10.1016\/j.neurol.2020.04.027_bib0795","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0333102418796842","article-title":"Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives","volume":"38","author":"Sussman","year":"2018","journal-title":"Cephalalgia"},{"issue":"10","key":"10.1016\/j.neurol.2020.04.027_bib0800","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40261-019-00827-z","article-title":"Cost-effectiveness analysis of erenumab versus onabotulinumtoxina for patients with chronic migraine attacks in Greece","volume":"39","author":"Giannouchos","year":"2019","journal-title":"Clin Drug Investig"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378720306093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378720306093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:41:05Z","timestamp":1758519665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378720306093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0035378720306093"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2020.04.027","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2020.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}